A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of sipavibart in healthy Japanese adults
Elsevier ·
The publisher did not provide an abstract — full text is available via the link below.
A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of sipavibart in healthy Japanese adults. // Journal of Infection and Chemotherapy. – URL: https://www.sciencedirect.com/science/article/pii/S1341321X26001765?dgcid=rss_sd_all
A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of sipavibart in healthy Japanese adults. Journal of Infection and Chemotherapy. https://www.sciencedirect.com/science/article/pii/S1341321X26001765?dgcid=rss_sd_all
“A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of sipavibart in healthy Japanese adults.” Journal of Infection and Chemotherapy.
@article{article54085,
title = {A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of sipavibart in healthy Japanese adults},
journal = {Journal of Infection and Chemotherapy},
url = {https://www.sciencedirect.com/science/article/pii/S1341321X26001765?dgcid=rss_sd_all}
}